Cedar Wealth Management’s BioMarin Pharmaceuticals BMRN Stock Holding History

Cedar Wealth Management’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-2	Closed	–	–	306
2022 Q3	$0	Hold	2	–	–	﹤0.01%	335
2022 Q2	$0	Sell	2 -2	-50%	-$159	﹤0.01%	347
2022 Q1	$0	Sell	4 -4	-50%	-$335	﹤0.01%	373
2021 Q4	$1K	Sell	8 -187	-96%	-$15.4K	﹤0.01%	357
2021 Q3	$15K	Buy	195 +45	+30%	+$3.55K	0.01%	217
2021 Q2	$13K	Buy	+150	New	+$11.9K	0.01%	223
2018 Q4	–	Sell	-52	Closed	-$5K	–	164
2018 Q3	$5K	Hold	52	–	–	﹤0.01%	143
2018 Q2	$5K	Buy	+52	New	+$4.55K	﹤0.01%	161

Other funds holding BMRN

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Cedar Wealth Management's BMRN Position: Q4 2022 in Review

Cedar Wealth Management sold out of BioMarin Pharmaceuticals (BMRN) in Q4 2022, closing a stake of 2 shares.

Cedar Wealth Management first reported a position in BMRN in Q2 2018 and held it in 8 quarters. The position peaked at $15K in Q3 2021. 580 funds tracked by Wall St. Rank hold BMRN as of Q4 2022.

Cedar Wealth Management reported no remaining BioMarin Pharmaceuticals position as of Q4 2022 after selling out during the quarter.
Cedar Wealth Management sold 2 BioMarin Pharmaceuticals shares in Q4 2022.
Cedar Wealth Management first reported a position in BioMarin Pharmaceuticals in Q2 2018 and held it in 8 quarters.
Cedar Wealth Management's BioMarin Pharmaceuticals position peaked at $15K in Q3 2021.
580 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q4 2022.

Based on Cedar Wealth Management's 13F filing for Q4 2022, filed 14 Feb 2023.